Merrimack Pharmaceuticals
MACK
$14.74
Share price
0.03%
Change (1 day)
18.73%
Change (1 year)
Categories
Revenue for Merrimack Pharmaceuticals (MACK)
Revenue in 2023 (TTM): N/A
In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Merrimack Pharmaceuticals from 2010 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | N/A | |
| 2022 | N/A | |
| 2021 | N/A | |
| 2020 | N/A | |
| 2019 | N/A | |
| 2018 | N/A | |
| 2017 | N/A | -100% |
| 2016 | $61.24 M | -31.39% |
| 2015 | $89.25 M | -13.13% |
| 2014 | $0.10 B | 115.03% |
| 2013 | $47.78 M | -2.32% |
| 2012 | $48.92 M | 42.98% |
| 2011 | $34.21 M | 68.51% |
| 2010 | $20.3 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $50.35 B | N/A | 🇫🇷 France |
 Geron GERN | $0.23 M | N/A | 🇺🇸 USA |
 Clovis Oncology CLVS | $0.13 B | N/A | 🇺🇸 USA |
 AVEO Oncology
AVEO | $94.31 M | N/A | 🇺🇸 USA |
 Eterna Therapeutics ERNA | $0.06 M | N/A | 🇺🇸 USA |